CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
CRISPR Therapeutics AG reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
CRISPR Therapeutics AG reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, five executives at CRISPR Therapeutics AG received on average a compensation package of $7.3M, a 84% increase compared to previous year.
Average pay of disclosed executives at CRISPR Therapeutics AG
Samarth Kulkarni, Chief Executive Officer, received $16M in total, which increased by 67% compared to 2018. 54% of Kulkarni's compensation, or $8.8M, was in stock awards. Kulkarni also received $439K in non-equity incentive plan, $6.5M in option awards, $550K in salary, as well as $5.6K in other compensation.
Lawrence O. Klein, Chief Operating Officer, received a compensation package of $6.1M. 65% of the compensation package, or $4M, was in stock awards.
Tony W. Ho, EVP, Research and Development, earned $6M in 2019, a 45% increase compared to previous year.
James R. Kasinger, General Counsel, received $4.2M in 2019, which increases by 33% compared to 2018.
Michael J. Tomsicek, Chief Financial Officer, earned $4M in 2019, a 79% increase compared to previous year.
Related executives
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
James Kasinger
CRISPR Therapeutics AG
General Counsel
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
You may also like
Source: SEC filing on April 24, 2020.